CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
暂无分享,去创建一个
Ying Cheng | Jianming Xu | Yunpeng Liu | F. Bi | Yuankai Shi | S. Qin | Yiping Zhang | G. Sun | Xiaohua Hu | Yi Luo | Jin Li | X. Ouyang | Yan Sun | R. Zheng | Zhehai Wang | Wei Liu | L. Bai | Q. Yao | Xiaohui He | Yuhong Li | Yigui Chen | Li-wei Wang